If you were to build a successful business, make acquisitions, nurture it, and then accept an acquisition bid from a large entity, many people might ride off into the sunset. But for two clients of That’s Nice, this was far from the case. They were keen to seek another opportunity, and had seen potential in the pioneering and exciting field of cell and gene therapy during their previous experience in biopharmaceuticals. They thus embarked on a plan to launch Brammer Bio, and establish it as a best-in-class CDMO serving this segment.
The entrepreneurs selected the name Brammer Bio, but initially the business plans were M&A-based and therefore largely confidential. The difficulty in this scenario is building a brand when you have little tangible that you can talk about. But there is a need for press releases, statements of intent, interviews, and investor documentation. So the basics of the brand are necessary to show substance. We worked with the founders to understand their vision for the business and began to build the brand based on what we felt would become its DNA.
The vision for Brammer Bio is to be the best-in-class contract manufacturer serving the cell and gene therapy market. This is somewhat new ground, as other companies have been in this segment for a while but very few CDMOs have focused exclusively on this space, particularly since over a decade ago, belief and investment in the segment had waned for a number of years. Brammer Bio offers services for autologous and allogeneic cell therapy for ex vivo gene therapy, and viral vector manufacturing for in-vivo gene therapy.
The Brammer Bio management team shared its mission – to be the best-in-class cell and gene therapy CDMO –and its vision – to enable its clients to improve patients’ health. This focus on personalized medicine, combined with the founders’ desire to offer flexible, customer-oriented approaches that had worked in their previous business, influenced the tagline, “Manufacturing. Personalized.”
To support the negotiations and efforts involved in acquisitions, deal structuring, and the foundations of business development, we embarked on designing a visual identity and all the tactics required to present the business as a serious, professional entity. These would equally be a foundation to build upon later. So an identity was designed, a website was developed, and platforms for all other communications and public relations were created. In the future, the basis is already in place for expansion into trade show marketing, advertising, leveraged thought leadership, and all the activities demanded as the business expands.
In March 2016, Brammer Bio merged with Florida Biologix and the combined entity retained the Brammer Bio brand. This immediately made the company a formal entity with active production. The company’s 45,000 ft2 site in Florida, which was expanded to 64,000 ft2, offers process development and Phase I/II clinical manufacturing. Later in 2016, Brammer added a 50,000 ft2 site in Lexington, MA for late-stage modified cell therapies.